Fuse, M. A., Dinh, C. T., Vitte, J., Kirkpatrick, J., Mindos, T., Plati, S. K., Young, J. I., Huang, J., Carlstedt, A., Franco, M. C., Brnjos, K., Nagamoto, J., Petrilli, A. M., Copik, A. J., Soulakova, J. N., Bracho, O., Yan, D., Mittal, R., Shen, R., Telischi, F. F., Morrison, H., Giovannini, M., Liu, X., Chang, L., & Fernandez-Valle, C. (2019). preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development. Neuro-oncology, 21(4), 486–497. http://access.bl.uk/ark:/81055/vdc_100092353575.0x000016